Tenax Therapeutics, Inc.

Release Summary

Tenax Therapeutics, Inc. (Nasdaq: TENX), announces levosimendan Phase 2 PH-HFpEF now on ClinicalTrials.gov, study initiation expected 3rd quarter

Tenax Therapeutics, Inc.